National Medical Products Administration
PulseAugur coverage of National Medical Products Administration — every cluster mentioning National Medical Products Administration across labs, papers, and developer communities, ranked by signal.
10 day(s) with sentiment data
-
Yiling Pharma subsidiary receives drug registration certificate for Tadalafil tablets
Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received a drug registration certificate from China's National Medical Products Administration for its Tadalafi…
-
Yipin Hong subsidiary's drug candidate APH03867 accepted for clinical trials
Yipin Hong's subsidiary, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for its clinical trial application for the innovative drug APH03867. This…
-
Jiangshan Oupai Appoints New Board Secretary; Huiyu Pharma's Cancer Drug Trial Accepted
Jiangshan Oupai has appointed Chen Chunjin as the company's board secretary, effective immediately. This move means the company's chairman, Wu Shuigen, will no longer perform the duties of the board secretary. Separatel…
-
Huayu Pharmaceutical's novel triple-target cancer therapy gains clinical trial approval
Huayu Pharmaceutical's subsidiary, Huayu Haiyue, has received approval from China's National Medical Products Administration to begin clinical trials for HY07121, a novel subcutaneous injection for advanced solid tumors…
-
SpaceX to Join Hang Seng Tech Index Post-IPO; Shanghai Pharma Drug Approved
SpaceX is set to be included in the Hang Seng Hong Kong and US Technology Index following its planned IPO in June 2026. The index provider will recalculate the weighting of its US-listed constituents to equal weight aft…
-
Angelikang Pharma Secures Approval for Etoricoxib Tablet in China
Angelikang Pharmaceutical has received approval from China's National Medical Products Administration for its etoricoxib tablet, a medication used to treat inflammatory conditions like osteoarthritis and gout. This appr…
-
Haisco's novel non-opioid painkiller HSK51155 enters clinical trials
Haisco Pharmaceutical Group has received acceptance for its clinical trial application for HSK51155 tablets from China's National Medical Products Administration. This drug is an orally administered small molecule non-o…
-
China Investment Corp. names new Deputy GM; Apple launches Siri AI
China Investment Corporation announced significant leadership changes, with Liu Haoling stepping down from his roles as Vice Chairman, General Manager, and Chief Investment Officer. Concurrently, Wu Yingchun has been ap…
-
Huadong Medicine subsidiary's facial filler application accepted for new indication
Huadong Medicine's subsidiary, Xinkelimayxue, has received acceptance for a change registration application for its medical device, Ellansé® S-type. This application seeks to expand the approved uses of the injectable p…
-
Dongcheng Pharma seeks approval for injectable nafamostat mesylate
Dongcheng Pharmaceutical's subsidiary, Yantai Dongcheng Northern Pharmaceutical, has received acceptance for its marketing authorization application for injectable nafamostat mesylate. This drug already has similar prod…
-
Kweihua Pharmaceutical's Ambroxol Oral Solution Application Accepted
Kweihua Pharmaceutical's subsidiary has received acceptance for its application to market Ambroxol Hydrochloride Oral Solution. The drug is intended for conditions involving viscous sputum and difficulty expectorating, …
-
US-China biotech rivalry looms amid record deal-making
The United States and China are on the verge of a new technological conflict, with biotechnology emerging as a potential focal point. Despite US pharmaceutical companies seeking drug candidates from China's burgeoning b…
-
Sino Biopharmaceutical partners for exclusive promotion of autoimmune gel
Sino Biopharmaceutical has entered into an exclusive promotion agreement with Beijing Puqi Pharmaceutical Technology for their innovative autoimmune drug, Pumeixiti Ni Gel. This collaboration grants Sino Biopharmaceutic…
-
China approves world's first invasive brain-computer chip
China has approved the world's first invasive brain-computer interface (BCI) chip, called NEO, developed by Neuracle Technology and Tsinghua University. This coin-sized device, implanted on the dura mater, translates br…
-
Angelikang subsidiary secures drug registration for anesthetic
Angelikang's subsidiary, Fujian Haixi United Pharmaceutical Co., Ltd., has received a Drug Registration Certificate for Isoflurane from China's National Medical Products Administration. Isoflurane is an anesthetic used …
-
China approves record 138 pediatric drugs in 2025
China's National Medical Products Administration has approved a record 138 new drugs for pediatric use in 2025, marking the fifth consecutive year of growth in this sector. This surge in approvals is attributed to suppo…
-
Fosun Pharma subsidiary's breast cancer drug approved in China
Fosun Pharma announced that its subsidiary, Shanghai Fosun Pharmaceutical Biotechnology Co., Ltd., has received approval from China's National Medical Products Administration for its Pertuzumab Injection. This approval …
-
Li Auto delivers 95K vehicles in Q1, Innocare's ITP drug accepted
Li Auto reported first-quarter deliveries of 95,142 vehicles, a 2.5% increase year-over-year, reclaiming the top sales spot among Chinese brands in the new energy vehicle market above 200,000 yuan. The company's first-q…
-
China's drug regulator approves wave of domestic innovative medicines
China's National Medical Products Administration (NMPA) has approved a significant number of domestically developed innovative medicines, with 15 out of 19 cleared this year originating from Chinese companies. This surg…
-
Mingpai Industrial halts Caibai stake reduction; Rejebio drug trial expands
Zhejiang Mingpai Industrial Co., Ltd. has decided to terminate its plan to reduce its stake in Caibai Co., Ltd., having not sold any shares. Concurrently, Shun Jing Pharmaceutical, a subsidiary of Rejebio, has received …